Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Smoking Treatment in SCCS
NCT03521141Phase 3Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of varenicline + nicotine patch and nicotine patch in Tobacco Use Disorder (TUD) (3 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Intervention Feasibility: Ability to Retain Participants at 6 months. Started May 2018; status: completed.
02
Drugs
varenicline + nicotine patchnicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03521141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521141.